My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aquestive Therapeutics, Inc.

< Previous 1 2 3 Next >
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST EBS GMDA
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Completes $45 Million Debt Refinancing
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.